-
1
-
-
77957341503
-
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma
-
20879881 10.1056/NEJMoa0911123 1:CAS:528:DC%2BC3cXht1WqtrnP
-
Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, Shimada H, Grupp SA, Seeger R, Reynolds CP, Buxton A, Reisfeld RA, Gillies SD, Cohn SL, Maris JM, Sondel PM (2010) Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 363:1324-1334
-
(2010)
N Engl J Med
, vol.363
, pp. 1324-1334
-
-
Yu, A.L.1
Gilman, A.L.2
Ozkaynak, M.F.3
London, W.B.4
Kreissman, S.G.5
Chen, H.X.6
Smith, M.7
Anderson, B.8
Villablanca, J.G.9
Matthay, K.K.10
Shimada, H.11
Grupp, S.A.12
Seeger, R.13
Reynolds, C.P.14
Buxton, A.15
Reisfeld, R.A.16
Gillies, S.D.17
Cohn, S.L.18
Maris, J.M.19
Sondel, P.M.20
more..
-
2
-
-
33748702052
-
Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification
-
16954472 10.1093/jnci/djj330 1:CAS:528:DC%2BD28Xps1yjtL0%3D
-
Asgharzadeh S, Pique-Regi R, Sposto R, Wang H, Yang Y, Shimada H, Matthay K, Buckley J, Ortega A, Seeger RC (2006) Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification. J Natl Cancer Inst 98:1193-1203
-
(2006)
J Natl Cancer Inst
, vol.98
, pp. 1193-1203
-
-
Asgharzadeh, S.1
Pique-Regi, R.2
Sposto, R.3
Wang, H.4
Yang, Y.5
Shimada, H.6
Matthay, K.7
Buckley, J.8
Ortega, A.9
Seeger, R.C.10
-
3
-
-
66349083007
-
Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages
-
19411762 10.1172/JCI37869 1:CAS:528:DC%2BD1MXntVCjt7s%3D
-
Song L, Asgharzadeh S, Salo J, Engell K, Wu HW, Sposto R, Ara T, Silverman AM, DeClerck YA, Seeger RC, Metelitsa LS (2009) Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages. J Clin Invest 119:1524-1536
-
(2009)
J Clin Invest
, vol.119
, pp. 1524-1536
-
-
Song, L.1
Asgharzadeh, S.2
Salo, J.3
Engell, K.4
Wu, H.W.5
Sposto, R.6
Ara, T.7
Silverman, A.M.8
Declerck, Y.A.9
Seeger, R.C.10
Metelitsa, L.S.11
-
4
-
-
84867052186
-
Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma
-
22927533 10.1200/JCO.2011.40.9169 1:CAS:528:DC%2BC38XhslSks77M
-
Asgharzadeh S, Salo JA, Ji L, Oberthuer A, Fischer M, Berthold F, Hadjidaniel M, Liu CW, Metelitsa LS, Pique-Regi R, Wakamatsu P, Villablanca JG, Kreissman SG, Matthay KK, Shimada H, London WB, Sposto R, Seeger RC (2012) Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma. J Clin Oncol 30:3525-3532
-
(2012)
J Clin Oncol
, vol.30
, pp. 3525-3532
-
-
Asgharzadeh, S.1
Salo, J.A.2
Ji, L.3
Oberthuer, A.4
Fischer, M.5
Berthold, F.6
Hadjidaniel, M.7
Liu, C.W.8
Metelitsa, L.S.9
Pique-Regi, R.10
Wakamatsu, P.11
Villablanca, J.G.12
Kreissman, S.G.13
Matthay, K.K.14
Shimada, H.15
London, W.B.16
Sposto, R.17
Seeger, R.C.18
-
5
-
-
0028153776
-
Immune function of patients receiving recombinant human interleukin-6 (IL-6) in a phase i clinical study: Induction of C-reactive protein and IgE and inhibition of natural killer and lymphokine-activated killer cell activity
-
8306367 1:STN:280:DyaK2c7jvV2ksA%3D%3D
-
Scheid C, Young R, McDermott R, Fitzsimmons L, Scarffe JH, Stern PL (1994) Immune function of patients receiving recombinant human interleukin-6 (IL-6) in a phase I clinical study: induction of C-reactive protein and IgE and inhibition of natural killer and lymphokine-activated killer cell activity. Cancer Immunol Immunother 38:119-126
-
(1994)
Cancer Immunol Immunother
, vol.38
, pp. 119-126
-
-
Scheid, C.1
Young, R.2
McDermott, R.3
Fitzsimmons, L.4
Scarffe, J.H.5
Stern, P.L.6
-
6
-
-
28644445445
-
Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity
-
16288283 10.1038/nm1325 1:CAS:528:DC%2BD2MXht1yisr3I
-
Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S, Pilon-Thomas S, Niu G, Kay H, Mule J, Kerr WG, Jove R, Pardoll D, Yu H (2005) Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 11:1314-1321
-
(2005)
Nat Med
, vol.11
, pp. 1314-1321
-
-
Kortylewski, M.1
Kujawski, M.2
Wang, T.3
Wei, S.4
Zhang, S.5
Pilon-Thomas, S.6
Niu, G.7
Kay, H.8
Mule, J.9
Kerr, W.G.10
Jove, R.11
Pardoll, D.12
Yu, H.13
-
7
-
-
56149090590
-
TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibody-dependent cellular cytotoxicity in human NK cells
-
18768831 1:CAS:528:DC%2BD1cXhtVKntL3J
-
Trotta R, Col JD, Yu J, Ciarlariello D, Thomas B, Zhang X, Allard J 2nd, Wei M, Mao H, Byrd JC, Perrotti D, Caligiuri MA (2008) TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibody-dependent cellular cytotoxicity in human NK cells. J Immunol 181:3784-3792
-
(2008)
J Immunol
, vol.181
, pp. 3784-3792
-
-
Trotta, R.1
Col, J.D.2
Yu, J.3
Ciarlariello, D.4
Thomas, B.5
Zhang, X.6
Allard II, J.7
Wei, M.8
Mao, H.9
Byrd, J.C.10
Perrotti, D.11
Caligiuri, M.A.12
-
8
-
-
0029120259
-
Regulation of NK cell functions by TGF-beta 1
-
7636180 1:CAS:528:DyaK2MXntFWntbg%3D
-
Bellone G, Aste-Amezaga M, Trinchieri G, Rodeck U (1995) Regulation of NK cell functions by TGF-beta 1. J Immunol 155:1066-1073
-
(1995)
J Immunol
, vol.155
, pp. 1066-1073
-
-
Bellone, G.1
Aste-Amezaga, M.2
Trinchieri, G.3
Rodeck, U.4
-
9
-
-
33646563695
-
Pro- and antiinflammatory cytokine signaling: Reciprocal antagonism regulates interferon-gamma production by human natural killer cells
-
16713975 10.1016/j.immuni.2006.03.016 1:CAS:528:DC%2BD28XlsFWqt74%3D
-
Yu J, Wei M, Becknell B, Trotta R, Liu S, Boyd Z, Jaung MS, Blaser BW, Sun J, Benson DM Jr, Mao H, Yokohama A, Bhatt D, Shen L, Davuluri R, Weinstein M, Marcucci G, Caligiuri MA (2006) Pro- and antiinflammatory cytokine signaling: reciprocal antagonism regulates interferon-gamma production by human natural killer cells. Immunity 24:575-590
-
(2006)
Immunity
, vol.24
, pp. 575-590
-
-
Yu, J.1
Wei, M.2
Becknell, B.3
Trotta, R.4
Liu, S.5
Boyd, Z.6
Jaung, M.S.7
Blaser, B.W.8
Sun, J.9
Benson, Jr.D.M.10
Mao, H.11
Yokohama, A.12
Bhatt, D.13
Shen, L.14
Davuluri, R.15
Weinstein, M.16
Marcucci, G.17
Caligiuri, M.A.18
-
10
-
-
33847611509
-
TGFbeta promotes conversion of CD16 + peripheral blood NK cells into CD16- NK cells with similarities to decidual NK cells
-
17360654 10.1073/pnas.0611098104 1:CAS:528:DC%2BD2sXjtVWlt7k%3D
-
Keskin DB, Allan DS, Rybalov B, Andzelm MM, Stern JN, Kopcow HD, Koopman LA, Strominger JL (2007) TGFbeta promotes conversion of CD16 + peripheral blood NK cells into CD16- NK cells with similarities to decidual NK cells. Proc Natl Acad Sci USA 104:3378-3383
-
(2007)
Proc Natl Acad Sci USA
, vol.104
, pp. 3378-3383
-
-
Keskin, D.B.1
Allan, D.S.2
Rybalov, B.3
Andzelm, M.M.4
Stern, J.N.5
Kopcow, H.D.6
Koopman, L.A.7
Strominger, J.L.8
-
11
-
-
77956111335
-
TGF-beta affects development and differentiation of human natural killer cell subsets
-
20540115 10.1002/eji.200939910 1:CAS:528:DC%2BC3cXpsF2rsbc%3D
-
Allan DS, Rybalov B, Awong G, Zuniga-Pflucker JC, Kopcow HD, Carlyle JR, Strominger JL (2010) TGF-beta affects development and differentiation of human natural killer cell subsets. Eur J Immunol 40:2289-2295
-
(2010)
Eur J Immunol
, vol.40
, pp. 2289-2295
-
-
Allan, D.S.1
Rybalov, B.2
Awong, G.3
Zuniga-Pflucker, J.C.4
Kopcow, H.D.5
Carlyle, J.R.6
Strominger, J.L.7
-
12
-
-
5644248080
-
RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo
-
15492287 10.1158/0008-5472.CAN-04-1627 1:CAS:528:DC%2BD2cXosFynu7Y%3D
-
Friese MA, Wischhusen J, Wick W, Weiler M, Eisele G, Steinle A, Weller M (2004) RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo. Cancer Res 64:7596-7603
-
(2004)
Cancer Res
, vol.64
, pp. 7596-7603
-
-
Friese, M.A.1
Wischhusen, J.2
Wick, W.3
Weiler, M.4
Eisele, G.5
Steinle, A.6
Weller, M.7
-
13
-
-
2942588777
-
Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients
-
15187109 1:CAS:528:DC%2BD2cXks1ahtbw%3D
-
Lee JC, Lee KM, Kim DW, Heo DS (2004) Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J Immunol 172:7335-7340
-
(2004)
J Immunol
, vol.172
, pp. 7335-7340
-
-
Lee, J.C.1
Lee, K.M.2
Kim, D.W.3
Heo, D.S.4
-
14
-
-
1942534043
-
The evolution of thalidomide and its IMiD derivatives as anticancer agents
-
15057291 10.1038/nrc1323 1:CAS:528:DC%2BD2cXis1Gmt7k%3D
-
Bartlett JB, Dredge K, Dalgleish AG (2004) The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 4:314-322
-
(2004)
Nat Rev Cancer
, vol.4
, pp. 314-322
-
-
Bartlett, J.B.1
Dredge, K.2
Dalgleish, A.G.3
-
15
-
-
19944430437
-
Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: Clinical application
-
15638853 10.1111/j.1365-2141.2004.05286.x 1:CAS:528:DC%2BD2MXhs1Grsr4%3D
-
Hayashi T, Hideshima T, Akiyama M, Podar K, Yasui H, Raje N, Kumar S, Chauhan D, Treon SP, Richardson P, Anderson KC (2005) Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol 128:192-203
-
(2005)
Br J Haematol
, vol.128
, pp. 192-203
-
-
Hayashi, T.1
Hideshima, T.2
Akiyama, M.3
Podar, K.4
Yasui, H.5
Raje, N.6
Kumar, S.7
Chauhan, D.8
Treon, S.P.9
Richardson, P.10
Anderson, K.C.11
-
16
-
-
79951977934
-
Safety, pharmacokinetics, and immunomodulatory effects of lenalidomide in children and adolescents with relapsed/refractory solid tumors or myelodysplastic syndrome: A Children's Oncology Group Phase i Consortium report
-
21149673 10.1200/JCO.2010.30.8387 1:CAS:528:DC%2BC3MXit1yhur0%3D
-
Berg SL, Cairo MS, Russell H, Ayello J, Ingle AM, Lau H, Chen N, Adamson PC, Blaney SM (2011) Safety, pharmacokinetics, and immunomodulatory effects of lenalidomide in children and adolescents with relapsed/refractory solid tumors or myelodysplastic syndrome: a Children's Oncology Group Phase I Consortium report. J Clin Oncol 29:316-323
-
(2011)
J Clin Oncol
, vol.29
, pp. 316-323
-
-
Berg, S.L.1
Cairo, M.S.2
Russell, H.3
Ayello, J.4
Ingle, A.M.5
Lau, H.6
Chen, N.7
Adamson, P.C.8
Blaney, S.M.9
-
17
-
-
11144355748
-
Phase i study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers
-
14997189 10.1038/sj.bjc.6601579 1:CAS:528:DC%2BD2cXhslWrs7o%3D
-
Bartlett JB, Michael A, Clarke IA, Dredge K, Nicholson S, Kristeleit H, Polychronis A, Pandha H, Muller GW, Stirling DI, Zeldis J, Dalgleish AG (2004) Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. Br J Cancer 90:955-961
-
(2004)
Br J Cancer
, vol.90
, pp. 955-961
-
-
Bartlett, J.B.1
Michael, A.2
Clarke, I.A.3
Dredge, K.4
Nicholson, S.5
Kristeleit, H.6
Polychronis, A.7
Pandha, H.8
Muller, G.W.9
Stirling, D.I.10
Zeldis, J.11
Dalgleish, A.G.12
-
18
-
-
23844435619
-
Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model
-
16115943 10.1158/1078-0432.CCR-05-0577 1:CAS:528:DC%2BD2MXos1Cis7k%3D
-
Hernandez-Ilizaliturri FJ, Reddy N, Holkova B, Ottman E, Czuczman MS (2005) Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. Clin Cancer Res 11:5984-5992
-
(2005)
Clin Cancer Res
, vol.11
, pp. 5984-5992
-
-
Hernandez-Ilizaliturri, F.J.1
Reddy, N.2
Holkova, B.3
Ottman, E.4
Czuczman, M.S.5
-
19
-
-
51649123319
-
Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells
-
18628480 10.1158/1078-0432.CCR-07-4405 1:CAS:528:DC%2BD1cXosFGiur8%3D
-
Wu L, Adams M, Carter T, Chen R, Muller G, Stirling D, Schafer P, Bartlett JB (2008) lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res 14:4650-4657
-
(2008)
Clin Cancer Res
, vol.14
, pp. 4650-4657
-
-
Wu, L.1
Adams, M.2
Carter, T.3
Chen, R.4
Muller, G.5
Stirling, D.6
Schafer, P.7
Bartlett, J.B.8
-
20
-
-
69549116054
-
Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo
-
19565649 10.1002/ajh.21468 1:CAS:528:DC%2BD1MXhtFOktLjO
-
Zhang L, Qian Z, Cai Z, Sun L, Wang H, Bartlett JB, Yi Q, Wang M (2009) Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo. Am J Hematol 84:553-559
-
(2009)
Am J Hematol
, vol.84
, pp. 553-559
-
-
Zhang, L.1
Qian, Z.2
Cai, Z.3
Sun, L.4
Wang, H.5
Bartlett, J.B.6
Yi, Q.7
Wang, M.8
-
21
-
-
29244488561
-
Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: Clinical implications
-
16357183 10.1158/0008-5472.CAN-05-1657 1:CAS:528:DC%2BD2MXhtlWiu7vJ
-
Tai YT, Li XF, Catley L, Coffey R, Breitkreutz I, Bae J, Song W, Podar K, Hideshima T, Chauhan D, Schlossman R, Richardson P, Treon SP, Grewal IS, Munshi NC, Anderson KC (2005) Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications. Cancer Res 65:11712-11720
-
(2005)
Cancer Res
, vol.65
, pp. 11712-11720
-
-
Tai, Y.T.1
Li, X.F.2
Catley, L.3
Coffey, R.4
Breitkreutz, I.5
Bae, J.6
Song, W.7
Podar, K.8
Hideshima, T.9
Chauhan, D.10
Schlossman, R.11
Richardson, P.12
Treon, S.P.13
Grewal, I.S.14
Munshi, N.C.15
Anderson, K.C.16
-
22
-
-
60749120363
-
The humanized CD40 antibody SGN-40 demonstrates pre-clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukaemia
-
19183192 10.1111/j.1365-2141.2008.07548.x 1:CAS:528:DC%2BD1MXkt12ntLk%3D
-
Lapalombella R, Gowda A, Joshi T, Mehter N, Cheney C, Lehman A, Chen CS, Johnson AJ, Caligiuri MA, Tridandapani S, Muthusamy N, Byrd JC (2009) The humanized CD40 antibody SGN-40 demonstrates pre-clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukaemia. Br J Haematol 144:848-855
-
(2009)
Br J Haematol
, vol.144
, pp. 848-855
-
-
Lapalombella, R.1
Gowda, A.2
Joshi, T.3
Mehter, N.4
Cheney, C.5
Lehman, A.6
Chen, C.S.7
Johnson, A.J.8
Caligiuri, M.A.9
Tridandapani, S.10
Muthusamy, N.11
Byrd, J.C.12
-
23
-
-
79953744107
-
Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: Influence of host immune and tumor markers
-
20848094 10.1007/s00262-010-0919-9 1:CAS:528:DC%2BC3MXht12gt74%3D
-
Wu L, Parton A, Lu L, Adams M, Schafer P, Bartlett JB (2011) Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers. Cancer Immunol Immunother 60:61-73
-
(2011)
Cancer Immunol Immunother
, vol.60
, pp. 61-73
-
-
Wu, L.1
Parton, A.2
Lu, L.3
Adams, M.4
Schafer, P.5
Bartlett, J.B.6
-
24
-
-
67651111993
-
Immunomodulatory drugs reorganize cytoskeleton by modulating Rho GTPases
-
19417207 10.1182/blood-2009-02-200543 1:CAS:528:DC%2BD1MXovVKlsr8%3D
-
Xu Y, Li J, Ferguson GD, Mercurio F, Khambatta G, Morrison L, Lopez-Girona A, Corral LG, Webb DR, Bennett BL, Xie W (2009) Immunomodulatory drugs reorganize cytoskeleton by modulating Rho GTPases. Blood 114:338-345
-
(2009)
Blood
, vol.114
, pp. 338-345
-
-
Xu, Y.1
Li, J.2
Ferguson, G.D.3
Mercurio, F.4
Khambatta, G.5
Morrison, L.6
Lopez-Girona, A.7
Corral, L.G.8
Webb, D.R.9
Bennett, B.L.10
Xie, W.11
-
25
-
-
0033956432
-
Neutrophils are cytotoxic and growth-inhibiting for neuroblastoma cells with an anti-GD2 antibody but, without cytotoxicity, can be growth-stimulating
-
10663607 10.1007/s002620050008 1:CAS:528:DC%2BD3cXhtlais7k%3D
-
Chen RL, Reynolds CP, Seeger RC (2000) Neutrophils are cytotoxic and growth-inhibiting for neuroblastoma cells with an anti-GD2 antibody but, without cytotoxicity, can be growth-stimulating. Cancer Immunol Immunother 48:603-612
-
(2000)
Cancer Immunol Immunother
, vol.48
, pp. 603-612
-
-
Chen, R.L.1
Reynolds, C.P.2
Seeger, R.C.3
-
26
-
-
0027237666
-
Selective long-term elimination of natural killer cells in vivo by an anti-interleukin 2 receptor beta chain monoclonal antibody in mice
-
8350049 10.1084/jem.178.3.1103 1:CAS:528:DyaK3sXlsFyjsr8%3D
-
Tanaka T, Kitamura F, Nagasaka Y, Kuida K, Suwa H, Miyasaka M (1993) Selective long-term elimination of natural killer cells in vivo by an anti-interleukin 2 receptor beta chain monoclonal antibody in mice. J Exp Med 178:1103-1107
-
(1993)
J Exp Med
, vol.178
, pp. 1103-1107
-
-
Tanaka, T.1
Kitamura, F.2
Nagasaka, Y.3
Kuida, K.4
Suwa, H.5
Miyasaka, M.6
-
27
-
-
33746547247
-
The biology of interleukin-2 and interleukin-15: Implications for cancer therapy and vaccine design
-
16868550 10.1038/nri1901 1:CAS:528:DC%2BD28Xnt1yisb0%3D
-
Waldmann TA (2006) The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol 6:595-601
-
(2006)
Nat Rev Immunol
, vol.6
, pp. 595-601
-
-
Waldmann, T.A.1
-
28
-
-
0017413143
-
Morphology, growth, chromosomal pattern and fibrinolytic activity of two new human neuroblastoma cell lines
-
856461 1:STN:280:DyaE2s7lvFyktQ%3D%3D
-
Seeger RC, Rayner SA, Banerjee A, Chung H, Laug WE, Neustein HB, Benedict WF (1977) Morphology, growth, chromosomal pattern and fibrinolytic activity of two new human neuroblastoma cell lines. Cancer Res 37:1364-1371
-
(1977)
Cancer Res
, vol.37
, pp. 1364-1371
-
-
Seeger, R.C.1
Rayner, S.A.2
Banerjee, A.3
Chung, H.4
Laug, W.E.5
Neustein, H.B.6
Benedict, W.F.7
-
29
-
-
0020044112
-
Definition of a Thy-1 determinant on human neuroblastoma, glioma, sarcoma, and teratoma cells with a monoclonal antibody
-
6172518 1:STN:280:DyaL38%2FpvFCqsg%3D%3D
-
Seeger RC, Danon YL, Rayner SA, Hoover F (1982) Definition of a Thy-1 determinant on human neuroblastoma, glioma, sarcoma, and teratoma cells with a monoclonal antibody. J Immunol 128:983-989
-
(1982)
J Immunol
, vol.128
, pp. 983-989
-
-
Seeger, R.C.1
Danon, Y.L.2
Rayner, S.A.3
Hoover, F.4
-
30
-
-
0022587520
-
Characterization of human neuroblastoma cell lines established before and after therapy
-
3456456 1:STN:280:DyaL287ksV2hsQ%3D%3D
-
Reynolds CP, Biedler JL, Spengler BA, Reynolds DA, Ross RA, Frenkel EP, Smith RG (1986) Characterization of human neuroblastoma cell lines established before and after therapy. J Natl Cancer Inst 76:375-387
-
(1986)
J Natl Cancer Inst
, vol.76
, pp. 375-387
-
-
Reynolds, C.P.1
Biedler, J.L.2
Spengler, B.A.3
Reynolds, D.A.4
Ross, R.A.5
Frenkel, E.P.6
Smith, R.G.7
-
31
-
-
0032401845
-
Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy
-
9850071 1:CAS:528:DyaK1cXotVSktb4%3D
-
Keshelava N, Seeger RC, Groshen S, Reynolds CP (1998) Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy. Cancer Res 58:5396-5405
-
(1998)
Cancer Res
, vol.58
, pp. 5396-5405
-
-
Keshelava, N.1
Seeger, R.C.2
Groshen, S.3
Reynolds, C.P.4
-
32
-
-
79951986245
-
Phase i trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: Pediatric Brain Tumor Consortium study PBTC-018
-
21149652 10.1200/JCO.2010.31.3601 1:CAS:528:DC%2BC3MXit1yhuro%3D
-
Warren KE, Goldman S, Pollack IF, Fangusaro J, Schaiquevich P, Stewart CF, Wallace D, Blaney SM, Packer R, Macdonald T, Jakacki R, Boyett JM, Kun LE (2011) Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: pediatric Brain Tumor Consortium study PBTC-018. J Clin Oncol 29:324-329
-
(2011)
J Clin Oncol
, vol.29
, pp. 324-329
-
-
Warren, K.E.1
Goldman, S.2
Pollack, I.F.3
Fangusaro, J.4
Schaiquevich, P.5
Stewart, C.F.6
Wallace, D.7
Blaney, S.M.8
Packer, R.9
Macdonald, T.10
Jakacki, R.11
Boyett, J.M.12
Kun, L.E.13
-
33
-
-
55049115076
-
Inhibition of the mevalonate pathway potentiates the effects of lenalidomide in myeloma
-
18621417 10.1016/j.leukres.2008.06.001
-
van der Spek E, Bloem AC, Lokhorst HM, van Kessel B, Bogers-Boer L, van de Donk NW (2009) Inhibition of the mevalonate pathway potentiates the effects of lenalidomide in myeloma. Leuk Res 33:100-108
-
(2009)
Leuk Res
, vol.33
, pp. 100-108
-
-
Van Der Spek, E.1
Bloem, A.C.2
Lokhorst, H.M.3
Van Kessel, B.4
Bogers-Boer, L.5
Van De Donk, N.W.6
|